Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate

International Journal of Biological Markers

Volumn 17, Issue 4, 2002, Pages 253-258

  Martinetti, A ^a   Seregni, E ^a   Ripamonti, C ^b   Ferrari, L ^a   De Conno, F ^b   Miceli, R ^c   Pallotti, F ^a   Coliva, A ^a   Biancolini, D ^a   Bombardieri, Emilio ^a  

^a Nuclear Medicine Division   (Italy)

^b Pio Albergo Trivulzio Geriatric I   (Italy)

^c Ist Naz per Studio/la Cura Tumori   (Italy)

Author keywords

Breast cancer metastases; Tartrate resistant acid phosphatase 5b; TRAP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ANALGESIC AGENT; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ACID PHOSPHATASE BLOOD LEVEL; ADULT; AGED; ANALGESIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; BREAST CANCER; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INFUSION; ENZYME BLOOD LEVEL; GENERAL CONDITION DETERIORATION; GENERAL CONDITION IMPROVEMENT; HUMAN; IMMUNOASSAY; IMMUNOLOGICAL MONITORING; OSTEOCLAST; PAIN ASSESSMENT; PALLIATIVE THERAPY; PREDICTION; STATISTICAL ANALYSIS;

EID: 0036822195     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.3147     Document Type: Article

References (24)

1. Body JJ. Metastatic bone disease: Clinical and therapeutic aspects. Bone 1992; 13 (Suppl 1): S57-62.
2. Hillner BE, Ingle JN, Bereson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000; 18: 1378-91.
3. Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain 1997; 69: 1-18.
4. Ripamonti C, Fulfaro F. Malignant bone pain: Pathophysiology and treatments. Curr Rev Pain 2000; 4: 187-96.
5. Koeberle D, Bacchus L, Thuerlimann B, Senn HJ. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: A prospective randomized double-blind trial. Support Care Cancer 1999; 7: 21-7.
6. Theriault RL, Lipton A, Hortobagy GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. J Clin Oncol 1999; 17: 846-56.
7. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-363.
8. Coleman RE, Purohit OP, Vinholes JJ, et al. High dose pamidronate: Clinical and biochemical effects in metastatic bone disease. Cancer 1997 (Suppl 8); 80: 1686-90.
9. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous Pamidronate: Results from a multinational randomized, controlled trial. J Clin Oncol 1996; 14: 2552-9.
10. Hortobagy GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with Pamidronate. J Clin Oncol 1998; 16: 2038-44.
11. Fleisch H. Bisphosphonates - Mechanisms of action. In: Burckhardt P, ed. Disodium Pamidronate (ADP) in the Treatment of Malignancy-Related Disorders. Toronto: Hans-Huber Publishers, 1988; 21-35.
12. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials. Pain 1998; 78: 157-69.
13. Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bone metastasis of breast cancer. Int J Clin Oncol 1999; 4: 331-7.
14. Garnero P, Delmans PD. Measurement of biochemical markers: Methods and limitations. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of Bone Biology. San Diego, CA: Academic Press, 1996; 1277-91.
15. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001; 47: 74-80.
16. Lau KHW, Onischi T, Wergedal JE, Singer FR, Baylink DJ. Characterization and assay of tartrate-resistant acid phosphatase activity in serum: Potential use to assess bone resorption. Clin Chem 1987; 33: 458-62.
17. Scarnecchia L, Minisola S, Pacitti MT, Carnevale V, Romagnoli E, Rosso R, Mazzuoli GF. Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 1991; 51: 517-24.
18. Alvarez L, Peris P, Bedini JL, et al. High bilirubin levels interfere with serum tartrate-resistant acid phosphatase determination: Relevance as a marker of bone resorption in jaundiced patients. Calcif Tissue Int 1999; 64: 301-3.
19. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila A, Väänänen HK. Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337-45.
20. Coombes RC, Dady P, Parson C, et al. Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer 1983; 52: 610-4.
21. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis 1978; 37: 378-81.
22. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: A comparison of six methods. Pain 1986; 27: 117-26.
23. Hortobagy GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91.
24. Hallen J, Hentunen TA, Hellman J, Vaananen HK. Tartrate resistant acid phosphatase from human bone: Purification and development of an immunoassay. J Bone Miner Res 1996; 11: 1444-52.